Semaglutide and tirzepatide are used to treat type 2 diabetes and manage obesity. Both are part of the glucagon-like peptide-1 receptor agonists (GLP-1 RAs) class, which work by mimicking the hormone GLP-1 to regulate blood sugar levels and aid in weight loss.
The key difference lies in their additional actions. While semaglutide exclusively targets GLP-1, tirzepatide also acts on glucose-dependent insulinotropic polypeptide (GIP), offering a dual approach. This unique mechanism of tirzepatide may enhance its effectiveness in weight loss. Clinical studies indicate that the combined effect on GLP-1 and GIP can provide more significant weight loss benefits compared to semaglutide alone. (Source)
Was this article helpful?
That’s Great!
Thank you for your feedback
Sorry! We couldn't be helpful
Thank you for your feedback
Feedback sent
We appreciate your effort and will try to fix the article